Inato
Inato has developed a global clinical trial marketplace that connects community-based research sites with top pharmaceutical sponsors, aiming to increase patient access and diversity in clinical research.
Inato's Mission
Inato's mission is to bring clinical research to each and every patient, regardless of who they are and where they live. By creating a global clinical trial marketplace, Inato aims to make clinical research more accessible and equitable. This mission guides the company's efforts to connect community-based research sites with global sponsor trials, ensuring that trials are brought to underrepresented communities across the globe.
Inato's Platform and Features
Inato's platform is designed to increase patient access to clinical trials worldwide. It connects community-based research sites to top-30 sponsor trials and is free for research sites to use. The platform includes a variety of features to streamline the research process, such as an Enrollment Plan that replaces traditional feasibility steps, a Verified Commitment calculator for realistic patient enrollment projections, and support for reusing data across multiple trials. Additionally, the platform highlights diversity efforts through a Diversity Assessment and Diversity Medals, and includes feedback mechanisms to reduce eligibility barriers.
Global Reach and Partnerships
Inato's platform has a significant global presence, with over 3,000 community research sites in more than 70 countries. The platform supports a third of the top 30 pharmaceutical companies, enabling them to find sites that meet their specific needs. By partnering with these major pharmaceutical companies, Inato facilitates the inclusion of diverse and underrepresented patient populations in clinical trials, ultimately aiming to improve health outcomes globally.
Recognition and Funding
Inato achieved notable recognition by Fast Company as one of the most innovative companies of 2024. This accolade underscores the impact of Inato's efforts in revolutionizing clinical trial access. Additionally, Inato successfully raised $20 million in Series A2 funding in 2023, showcasing the confidence investors have in the company's vision and the potential for continued growth and innovation in the clinical research sector.
Enhanced Enrollment and Diversity Rates
Inato's platform has demonstrated substantial improvements in clinical trial enrollment and diversity. The platform achieves 2.3x higher enrollment rates, 2.2x higher diverse enrollment rates, and 2.7x faster activation compared to traditional methods. By providing end-to-end support to both sponsors and sites, Inato ensures streamlined processes, leading to these impressive metrics. The focus on diversity and equitable access helps sponsors reach a broader and more inclusive patient population, driving innovation in clinical research.